Cost-effectiveness of daclatasvir plus asunaprevir for chronic hepatitis C genotype 1b treatment-naïve patients in China

BACKGROUND: Hepatitis C is the second fastest growing infectious disease in China. The standard-of-care for chronic hepatitis C in China is Pegylated interferon plus ribavirin (PR), which is associated with tolerability and efficacy issues. An interferon- and ribavirin-free, all-oral regimen compris...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Yun, Jin, Xiuze, Duan, Cheng-a-xin, Chang, Feng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5892899/
https://www.ncbi.nlm.nih.gov/pubmed/29634736
http://dx.doi.org/10.1371/journal.pone.0195117

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5892899/
https://www.ncbi.nlm.nih.gov/pubmed/29634736
http://dx.doi.org/10.1371/journal.pone.0195117

Ejemplares similares